interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Semaglutide

Generic competition · all medicines · read 12 November 2026

Is there a generic of Semaglutide, and who makes it?

Semaglutide appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Semaglutide2 dosage-form groups in the Orange Book
0generic makers listed
  1. Semaglutide appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Solution, Subcutaneous

Brand listed, no generic listed as marketed

Brand listed as marketed: Ozempic, Wegovy, Wegovy Flextouch and Wegovy Hd. No generic is listed as marketed.

201520202025203020352040204501brand 2017data datePatent 8129343 listed to expire 5 December 2031Patent 10335462 listed to expire 21 June 2033Patent 9764003 listed to expire 21 June 2033Patent 12569543 listed to expire 28 April 2037Patent 12214017 listed to expire 24 August 2038Patent 11752198 listed to expire 24 August 2038Patent 10888605 listed to expire 24 August 2038Patent 12295988 listed to expire 10 October 2038Patent 12551536 listed to expire 10 October 2038Patent 12029779 listed to expire 10 October 2038Patent 11478533 listed to expire 13 May 2040Patent 11318191 listed to expire 17 February 2041Exclusivity I-935 to 8 March 2027Exclusivity I-961 to 28 January 2028Exclusivity I-973 to 15 August 2028Exclusivity NS to 19 March 2029
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 8 March 2027Exclusivity I-935 Wegovy
  • 28 January 2028Exclusivity I-961 Ozempic
  • 15 August 2028Exclusivity I-973 Wegovy
  • 19 March 2029Exclusivity NS Wegovy Hd
  • 5 December 2031Patent 8129343 drug substance
  • 21 June 2033Patent 10335462
  • 21 June 2033Patent 9764003
  • 28 April 2037Patent 12569543
  • 24 August 2038Patent 12214017 drug product
  • 24 August 2038Patent 11752198 drug product
  • 24 August 2038Patent 10888605 drug product
  • 10 October 2038Patent 12295988

4 more patents are listed.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Ozempic, Rybelsus and Wegovy. No generic is listed as marketed.

20152020202520302035204001brand 2019data datePatent 8129343 listed to expire 5 December 2031Patent 11382957 listed to expire 16 December 2031Patent 9278123 listed to expire 16 December 2031Patent 10960052 listed to expire 16 December 2031Patent 10086047 listed to expire 16 December 2031Patent 11759503 listed to expire 15 March 2033Patent 10933120 listed to expire 15 March 2033Patent 11759501 listed to expire 15 March 2033Patent 11759502 listed to expire 15 March 2033Patent 12594326 listed to expire 15 March 2033Patent 11033499 listed to expire 19 June 2033Patent 12514822 listed to expire 2 May 2034Patent 12239739 listed to expire 2 May 2034Patent 10278923 listed to expire 2 May 2034Patent 11833248 listed to expire 1 February 2039Patent 12396953 listed to expire 1 February 2039Exclusivity I-935 to 8 March 2027Exclusivity I-976 to 17 October 2028Exclusivity NP to 22 December 2028
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 8 March 2027Exclusivity I-935 Wegovy
  • 17 October 2028Exclusivity I-976 Ozempic
  • 22 December 2028Exclusivity NP Wegovy
  • 5 December 2031Patent 8129343 drug substance
  • 16 December 2031Patent 11382957 drug substance
  • 16 December 2031Patent 9278123 drug substance
  • 16 December 2031Patent 10960052 drug product
  • 16 December 2031Patent 10086047 drug product
  • 15 March 2033Patent 11759503 drug product
  • 15 March 2033Patent 10933120 drug product
  • 15 March 2033Patent 11759501 drug product

8 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.